Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of “Hold” by Brokerages

Spruce Biosciences, Inc. (NASDAQ:SPRB) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold rating. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $3.90.

SPRB has been the subject of a number of research reports. Citizens Jmp cut Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. HC Wainwright reiterated a “neutral” rating on shares of Spruce Biosciences in a research report on Monday, December 16th. Royal Bank of Canada restated a “sector perform” rating and issued a $1.50 price target (down previously from $2.00) on shares of Spruce Biosciences in a research report on Wednesday, December 11th. JMP Securities restated a “market perform” rating and issued a $3.00 price target on shares of Spruce Biosciences in a research report on Wednesday, December 11th. Finally, Oppenheimer restated a “market perform” rating on shares of Spruce Biosciences in a research report on Wednesday, December 11th.

Spruce Biosciences Stock Down 0.0 %

Spruce Biosciences stock opened at $0.41 on Friday. The stock has a market cap of $16.94 million, a PE ratio of -0.44 and a beta of 2.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.36 and a current ratio of 5.36. Spruce Biosciences has a one year low of $0.34 and a one year high of $5.95. The stock has a fifty day moving average of $0.40 and a 200 day moving average of $0.46.

Spruce Biosciences (NASDAQ:SPRB) last posted its quarterly earnings data on Monday, November 11th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $1.80 million. Spruce Biosciences had a negative return on equity of 62.10% and a negative net margin of 555.23%. As a group, sell-side analysts predict that Spruce Biosciences will post -1 EPS for the current year.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.